MRD refers to the small number of cancer cells that remain in the body after treatment. In this episode, Gail Roboz, MD, from Weill Cornell Medical College, provides an overview of MRD, including understanding its definition, explains the role advancements in technology have played in detection, and underscores the importance of understanding to what degree this detection can be helpful. Dr. Roboz provides strategies to communicate with patients about the impact of MRD on prognosis, treatment and outcomes and discusses the future of MRD testing in blood cancers.

Featuring an interview with Dr Steven Coutre on the following topics: Front-line treatment of CLL (0:00) Recent data with ibrutinib-based regimens as first-line therapy for CLL (5:31) Results of the Phase III ELEVATE-TN study evaluating the efficacy and safety of acalabrutinib with obinutuzumab compared to acalabrutinib alone or obinutuzumab with chlorambucil for treatment-naive CLL (14:22) Case: A man in his late 70s experiences atrial fibrillation after receiving ibrutinib as first-line treatment for CLL (19:08) Case: A woman in her early 60s develops arthralgias after treatment with ibrutinib for CLL (25:08) Case: A man in his early 70s receiving ibrutinib for CLL experiences easy bruising on his forearms (27:28) Results from the CLL14 trial evaluating the addition of venetoclax versus chlorambucil to obinutuzumab for patients with previously untreated CLL and coexisting medical conditions (32:06) Monitoring and management of tumor lysis syndrome (TLS) in patients receiving venetoclax (37:07) Impact of minimal residual disease (MRD) assessment on outcomes for patients with CLL (41:26) Spectrum of adverse events with Bruton tyrosine kinase (BTK) inhibitors for CLL (46:22) CME information and select publications.

Featuring discussions on the role of minimal residual disease evaluation in the management of multiple myeloma and chronic lymphocytic leukemia with Drs Shaji Kumar and Philip Thompson, moderated by Dr Neil Love.

In this podcast, we�ll look at research demonstrating that the histone acetyltransferase HBO1 is an essential regulator of hematopoietic stem cell function during adult hematopoiesis. Next, we�ll review a large, combined analysis confirming the prognostic value of MRD assessed with next-generation sequencing in 4 randomized trials evaluating daratumumab-based therapies. We�ll conclude with research demonstrating that ferroptosis, a specific type of regulated cell death, is a key mechanism of cardiomyopathy in sickle cell disease.

In this episode, we will review a study that shows that non-invasive imaging of T cell metabolic activity can detect early graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, learn more about how detailed assessment of measurable residual disease in multiple myeloma can better define outcomes and how treatment resistance arises, and finally, examine the mechanism of action and pharmacokinetics of Ciraparantag, a small molecule being developed to rapidly reverse the effects of anticoagulants.

Drs. Rafael Fonseca and Tara Graff�discuss the benefits of MRD testing for patients with Multiple Myeloma and CLL, the importance of training the multidisciplinary care team, and the promise of MRD testing to improve patient outcomes as its adoption continues to grow.

Of all the hematologic malignancies, multiple myeloma has one of the greatest disparities in incidence and prevalence, with incidence in African American patients more than twice that in white patients. These podcasts will teach clinicians culturally sensitive approaches for management of multiple myeloma in African Americans, how to address barriers due to racial disparities, and strategies to implement newly gained knowledge for the best outcomes of African American patients with multiple myeloma.

In this podcast, we chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more.

This palm card provides a list of support services offered by LLS.

This palm card provides an overview of financial assistance programs offered by LLS.

In this retrospective study, we present the results from a multinational and multicenter series of 400 patients with MRD monitoring during front-line therapy with the aim of exploring how clinical decisions made based on those MRD results affected outcomes...Herein, we find that MRD is useful in guiding clinical decisions during initial therapy and has a positive impact on PFS in MM patients. This potentially opens a new dimension for the use of MRD in MM, but this role still remains to be confirmed in prospective, randomized clinical trials.

Studies have demonstrated that achievement of MRD negativity after induction chemotherapy or during consolidation is associated with significantly better long-term outcomes, and MRD status constitutes an independently prognostic marker, often superseding other conventional risk factors.

Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis�This study aimed to confirm the activity and safety profile of blinatumomab for ALL.

Our results confirm that sCR does not predict a different outcome and indicate that more sensitive techniques are able to identify patients with differing prognoses. We suggest that MRD categories should be implemented over sCR for the future classification of MM responses.

Due to small sample size, adjusted models could not be constructed for sCR or MRD. Nevertheless, evidence of significant survival benefit (p<0.05) associated with MRD negativity and sCR was identified across real-world studies. These findings provide support for the use of response outcomes as surrogate endpoints to estimate PFS benefit in NDMM.

Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population.

This Review presents an overview of the various techniques for MRD detection in patients with MM. In addition, this article discusses challenges and opportunities for the routine use of MRD testing, possible future directions for clinical trials and implications for drug approval processes.

Authors identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19� relapse to chimeric antigen receptor (CAR) therapy.

This review aims to critically analyze the key MRD aspects including the current evidence supporting the use of MRD in clinical practice and the pitfalls of the various methods used to assess MRD. The utility of MRD for light chain (AL) amyloidosis will also be discussed.

Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification and quantification of minimal residual disease (MRD) in lymphoid neoplasms has been the focus of intense research, development and application. However, standardization and validation in a scientifically controlled multicentre setting is still lacking.